CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
实体瘤与转移灶中的 CAR-T 细胞：开辟前行之路
英文原题：CAR T cells in solid tumors and metastasis: paving the way forward.
查看英文原题
CAR T cells in solid tumors and metastasis: paving the way forward.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法因其在血液系统恶性肿瘤中的显著疗效而被誉为癌症治疗的一项突破，但在应用于实体瘤时却面临重大障碍。尽管在这些患者中对CAR-T 细胞的显著应答仍然只是零星出现，但由于诸如靶向非肿瘤毒性、其向肿瘤的转运和浸润困难，以及存在充满敌意且具有免疫抑制作用的微环境等问题，挑战依然持续存在。本综述旨在探讨近期为克服CAR-T 细胞疗法治疗实体瘤中这些障碍所做的努力。具体而言，我们将深入探讨通过抗原靶向来增强肿瘤特异性、应对肿瘤异质性、克服物理屏障以及抵消免疫抑制微环境的有前景策略。
展开英文摘要原文
CAR T cell therapy, hailed as a breakthrough in cancer treatment due to its remarkable outcomes in hematological malignancies, encounters significant hurdles when applied to solid tumors. While notable responses to CAR T cells remain sporadic in these patients, challenges persist due to issues such as on-target off-tumor toxicity, difficulties in their trafficking and infiltration into the tumor, and the presence of a hostile and immunosuppressive microenvironment.
This review aims to explore recent endeavors aimed at overcoming these obstacles in CAR T cell therapy for solid tumors. Specifically, we will delve into promising strategies for enhancing tumor specificity through antigen targeting, addressing tumor heterogeneity, overcoming physical barriers, and counteracting the immune-suppressive microenvironment.
论文信息
- 作者
- Sirini C、De Rossi L、Moresco MA、Casucci M
- 第一作者单位
- Innovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132, Milan, Italy.Italy
- 通讯作者单位
- Innovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132, Milan, Italy. casucci.monica@hsr.it.Italy
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Cancer metastasis reviews2024 Dec
- 原文标识
- PubMed 39316265 · DOI 10.1007/s10555-024-10213-7